<DOC>
	<DOCNO>NCT01862640</DOCNO>
	<brief_summary>To compare efficacy 2 fixed dos brexpiprazole placebo subject agitation associate dementia Alzheimer 's type .</brief_summary>
	<brief_title>A Study Two Fixed-doses Brexpiprazole Treatment Subjects With Agitation Associated With Dementia Alzheimer 's Type</brief_title>
	<detailed_description>Behavioral symptom , agitation , core feature subject Alzheimer 's disease relate dementias develop majority dementia subject . The presence agitation subject Alzheimer 's disease place significant burden subject caregiver also healthcare system . This trial design assess safety efficacy brexpiprazole treatment subject agitation associate dementia Alzheimer 's Type . The trial consist continuous 12-week double-blind treatment period 30-day follow-up . The trial population include male female subject 55 90 year age ( inclusive ) diagnosis probable Alzheimer 's disease , reside either institutionalized set non-institutionalized setting subject live alone .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Male female subject 55 90 year age , inclusive , time informed consent . Subjects reside current location least 14 day screen expected remain location duration trial . Subjects diagnosis probable Alzheimer 's disease accord NINCDSADRDA . Subjects MMSE score 5 22 , inclusive , screen baseline visit . Subjects onset symptom agitation least 2 week prior screen visit . Subjects score â‰¥ 4 agitation/aggression item NPINH screen baseline visit . Subjects require pharmacotherapy treatment agitation per investigator 's judgment , evaluation reversible factor ( eg , pain , infection , polypharmacy ) trial nonpharmacological intervention . Subjects must previous MRI CT scan brain , perform onset symptom dementia , finding consistent diagnosis Alzheimer 's disease . Subjects dementia memory impairment due Alzheimer 's disease Subjects history stroke , welldocumented transient ischemic attack , pulmonary cerebral embolism . Subjects currently clinically significant neurological , hepatic , renal , metabolic , hematological , immunological , cardiovascular , pulmonary , gastrointestinal , psychiatric disorder . Subjects diagnose Axis I disorder ( DSMIVTR criterion ) Subjects uncontrolled hypertension Subjects uncontrolled insulindependent diabetes mellitus ( IDDM ) Subjects epilepsy history seizure Subjects consider poor general health base investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OPC-34712</keyword>
	<keyword>brexpiprazole</keyword>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Memory</keyword>
	<keyword>Agitation</keyword>
</DOC>